Among these, cytokeratin-18 (CK-18), a fragment released during hepatocyte apoptosis, is the most extensively studied serum biomarker for distinguishing NASH from simple steatosis. This evidence concerns the gene KRT18 and metabolic dysfunction-associated steatohepatitis.